Trump Links Tylenol, Vaccines to Autism
Analysis based on 8 articles · First reported Sep 22, 2025 · Last updated Sep 23, 2025
Donald Trump's statements linking Tylenol and vaccines to autism caused Kenvue's shares to fall 7.5%, reducing its market value by $2.6 billion, indicating a direct negative impact on the pharmaceutical industry. The broader market sentiment is negative due to the promotion of unproven medical claims by a high-ranking official, potentially undermining public trust in established health authorities like the United States — Food and Drug Administration and United States — Centers for Disease Control and Prevention.
President Donald Trump used his presidential platform to promote unproven ties between Tylenol (acetaminophen) and vaccines with autism. He instructed pregnant women to avoid Tylenol and announced that the United States — Food and Drug Administration would begin notifying doctors of a potential association, despite a lack of immediate medical evidence. Health Secretary Robert F. Kennedy Jr., at Donald Trump's urging, launched an 'all-agency' effort involving the United States — National Institutes of Health, United States — Food and Drug Administration, United States — Centers for Disease Control and Prevention, and United States — Centers for Medicare & Medicaid Services to identify autism causes. Medical experts, including the Society for Maternal-Fetal Medicine and the American College of Obstetricians and Gynecologists, criticized Donald Trump's remarks as irresponsible and lacking evidence. Kenvue, the maker of Tylenol, disputed the claims, and its shares fell 7.5%, resulting in a $2.6 billion market value reduction. United States — Food and Drug Administration Commissioner Marty Makary also announced steps to approve leucovorin as a treatment for low folate levels, which may include some people with autism.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard